Published: 15 October, 2026 DOI:10.22514/ejgo.2026.061

CORRECTION

European Journal of Gynaecological Oncology

Correction: The role of progesterone in ovarian cancer from pathogenesis to personalized therapy: an updated mini-review

Iara Fernandes[1,†], Rita Coelho[2,*,†], Margarida Figueiredo-Dias[1], Ricardo Roque[2]

[1]Faculty of Medicine, Gynecology University Clinic, University of Coimbra, 3000-548 Coimbra, Portugal
[2]Medical Oncology Department, Portuguese Institute of Oncology of Coimbra, 3000-075 Coimbra, Portugal

***Correspondence**

4126@ipocoimbra.min-saude.pt (Rita Coelho)

[†] These authors contributed equally.

After careful post-publication review, two references were found to have been inadvertently mismatched with the corresponding statements and were not the most appropriate citations to support the relevant content in the original article [1]. These corrections concern the bibliography only and do not affect the scientific content, interpretation, or conclusions of the manuscript.

The corrections are as follows:

Correction to Reference 31 (Section 4.5.4)

The original citation:

Tripathy S, Nallasamy S, Mahendroo M. Progesterone and its receptor signaling in cervical remodeling: mechanisms of physiological actions and therapeutic implications. The Journal of Steroid Biochemistry and Molecular Biology. 2022; 223: 106137.

Has been replaced by an appropriate reference already included in the article (Reference 6):

Mauro LJ, Spartz A, Austin JR, Lange CA. Reevaluating the role of progesterone in ovarian cancer: is progesterone always protective? Endocrine Reviews. 2023; 44: 1029–1046.

This reference directly supports the discussion regarding progesterone receptor signalling and its interaction with oncogenic pathways in ovarian cancer.

Correction to Reference 38 (Section 5.2)

The original citation:

Welsh L, Panek R, Riddell A, Wong K, Leach MO, Tavassoli M, *et al.* Blood transfusion during radical chemoradiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. British Journal of Cancer. 2017; 116: 28–35.

Has been replaced by:

Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, *et al.* Chemotherapy *vs* tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist). British Journal of Cancer. 2017; 116: 455–463.

This study directly supports the statement regarding tamoxifen as a lower-toxicity treatment option in platinum-resistant ovarian cancer.

In addition, the authors have carefully reviewed all remaining references in the article to ensure they appropriately support the corresponding statements. The authors apologize for these citation errors.

REFERENCES

[1] Fernandes I, Coelho R, Figueiredo-Dias M, Roque R. The role of progesterone in ovarian cancer from pathogenesis to personalized therapy: an updated mini-review. European Journal of Gynaecological Oncology. 2025; 46: 5–13.

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

 ©2026 The Author(s). Published by MRE Press.